213 related articles for article (PubMed ID: 21493729)
1. Clinically silent somatotroph adenomas are common.
Wade AN; Baccon J; Grady MS; Judy KD; O'Rourke DM; Snyder PJ
Eur J Endocrinol; 2011 Jul; 165(1):39-44. PubMed ID: 21493729
[TBL] [Abstract][Full Text] [Related]
2. 'Silent' somatotropinoma.
Pawlikowski M; Kuta J; Fuss-Chmielewska J; Winczyk K
Endokrynol Pol; 2012; 63(2):88-91. PubMed ID: 22538745
[TBL] [Abstract][Full Text] [Related]
3. Modification of hormonal secretion in clinically silent pituitary adenomas.
Daems T; Verhelst J; Michotte A; Abrams P; De Ridder D; Abs R
Pituitary; 2009; 12(1):80-6. PubMed ID: 18350381
[TBL] [Abstract][Full Text] [Related]
4. Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary.
Yamada S; Sano T; Stefaneanu L; Kovacs K; Aiba T; Sawano S; Shishiba Y
J Clin Endocrinol Metab; 1993 Feb; 76(2):352-6. PubMed ID: 8432778
[TBL] [Abstract][Full Text] [Related]
5. Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience.
Langlois F; Lim DST; Varlamov E; Yedinak CG; Cetas JS; McCartney S; Dogan A; Fleseriu M
Endocrine; 2017 Dec; 58(3):528-534. PubMed ID: 29043561
[TBL] [Abstract][Full Text] [Related]
6. Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas.
Lekva T; Berg JP; Lyle R; Heck A; Ringstad G; Olstad OK; Michelsen AE; Casar-Borota O; Bollerslev J; Ueland T
Endocrinology; 2013 Sep; 154(9):3331-43. PubMed ID: 23825128
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
[TBL] [Abstract][Full Text] [Related]
8. Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.
Cheng S; Al-Agha R; Araujo PB; Serri O; L Asa S; Ezzat S
PLoS One; 2013; 8(9):e73543. PubMed ID: 24039977
[TBL] [Abstract][Full Text] [Related]
9. Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma.
Nasr C; Mason A; Mayberg M; Staugaitis SM; Asa SL
J Clin Endocrinol Metab; 2006 Dec; 91(12):4776-80. PubMed ID: 16968791
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype.
Lee CC; Vance ML; Lopes MB; Xu Z; Chen CJ; Sheehan J
Pituitary; 2015 Jun; 18(3):326-34. PubMed ID: 24925503
[TBL] [Abstract][Full Text] [Related]
11. Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1.
Hozumi K; Fukuoka H; Odake Y; Takeuchi T; Uehara T; Sato T; Inoshita N; Yoshida K; Matsumoto R; Bando H; Hirota Y; Iguchi G; Taniguchi M; Otsuki N; Nishigori C; Kosaki K; Hasegawa T; Ogawa W; Takahashi Y
Endocr J; 2019 Oct; 66(10):853-857. PubMed ID: 31189769
[TBL] [Abstract][Full Text] [Related]
12. Early surgical intervention for patients with possible clinically silent somatotroph adenoma: a case series.
Kawaguchi T; Ogawa Y; Tominaga T
J Med Case Rep; 2019 Mar; 13(1):85. PubMed ID: 30862315
[TBL] [Abstract][Full Text] [Related]
13. Acromegaly without imaging evidence of pituitary adenoma.
Lonser RR; Kindzelski BA; Mehta GU; Jane JA; Oldfield EH
J Clin Endocrinol Metab; 2010 Sep; 95(9):4192-6. PubMed ID: 20610592
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
15. Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up.
Lv L; Jiang Y; Yin S; Hu Y; Chen C; Ma W; Jiang S; Zhou P
Endocrine; 2019 Nov; 66(2):310-318. PubMed ID: 31368083
[TBL] [Abstract][Full Text] [Related]
16. Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas/somatotroph pituitary neuroendocrine tumors.
Yamato A; Nagano H; Gao Y; Matsuda T; Hashimoto N; Nakayama A; Yamagata K; Yokoyama M; Gong Y; Shi X; Zhahara SN; Kono T; Taki Y; Furuki N; Nishimura M; Horiguchi K; Iwadate Y; Fukuyo M; Rahmutulla B; Kaneda A; Hasegawa Y; Kawashima Y; Ohara O; Ishikawa T; Kawakami E; Nakamura Y; Inoshita N; Yamada S; Fukuhara N; Nishioka H; Tanaka T
Commun Biol; 2022 Nov; 5(1):1304. PubMed ID: 36435867
[TBL] [Abstract][Full Text] [Related]
17. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor.
Kola B; Korbonits M; Diaz-Cano S; Kaltsas G; Morris DG; Jordan S; Metherell L; Powell M; Czirják S; Arnaldi G; Bustin S; Boscaro M; Mantero F; Grossman AB
Clin Endocrinol (Oxf); 2003 Sep; 59(3):328-38. PubMed ID: 12919156
[TBL] [Abstract][Full Text] [Related]
18. Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature.
Chinezu L; Vasiljevic A; Trouillas J; Lapoirie M; Jouanneau E; Raverot G
Eur J Endocrinol; 2017 Feb; 176(2):195-201. PubMed ID: 27913611
[TBL] [Abstract][Full Text] [Related]
19. Silent somatotroph pituitary adenomas: an update.
Langlois F; Woltjer R; Cetas JS; Fleseriu M
Pituitary; 2018 Apr; 21(2):194-202. PubMed ID: 29305680
[TBL] [Abstract][Full Text] [Related]
20. Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly?
Garcia EA; Trivellin G; Aflorei ED; Powell M; Grieve J; Alusi G; Pobereskin L; Shariati B; Cudlip S; Roncaroli F; Mendoza N; Grossman AB; Harper EA; Korbonits M
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1918-26. PubMed ID: 24152687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
